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Abstract
Methylglyoxal (MG) is a highly reactive metabolite physiologically presented in all biological systems. The effects of MG on
diabetes and hypertension have been long recognized. In the present study, we investigated the potential role of MG in
obesity, one of the most important factors to cause metabolic syndrome. An increased MG accumulation was observed in
the adipose tissue of obese Zucker rats. Cell proliferation assay showed that 5–20 mM of MG stimulated the proliferation of
3T3-L1 cells. Further study suggested that accumulated-MG stimulated the phosphorylation of Akt1 and its targets
including p21 and p27. The activated Akt1 then increased the activity of CDK2 and accelerated the cell cycle progression of
3T3-L1 cells. The effects of MG were efficiently reversed by advanced glycation end product (AGE) breaker alagebrium and
Akt inhibitor SH-6. In summary, our study revealed a previously unrecognized effect of MG in stimulating adipogenesis by
up-regulation of Akt signaling pathway and this mechanism might offer a new approach to explain the development of
obesity.
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Introduction
Methylglyoxal (MG) is a reactive dicarbonyl compound that
interacts with certain free amino acid residues in proteins and
forms advanced glycation endproducts (AGEs) [1]. It is derived
from glycolysis as well as lipid and protein catabolism [2,3]. MG-
induced reactive oxygen species (ROS) [4,5,6,7] and MG-derived
protein modifications [8,9] have been addressed as possible causal
factors for insulin resistance in vitro and in vivo. Moreover, increased
accumulation of MG and AGEs were observed in diabetic
[10,11,12] and hypertensive [11,13,14] animals and patients.
The full name of alagebrium is 3-(2-oxo-2-phenyl)- ethyl-4, 5-
dimethyl-thiazolium chloride. It is a stable derivative of N-
phenacylthiazolium bromide (PTB). For its significant effects of
reducing AGEs in vivo and in vitro [15,16], alagebrium has been
applied in animal and clinical studies to treat hypertension and
cardiovascular complications by regaining flexibility and function-
ality of the vascular system (13).
As the most important risk factor for hypertension and diabetes,
obesity is well recognized as a result of excessive consumption of
fat and carbohydrates, which are both precursors of MG and
AGEs. The association between obesity and diabetes and
hypertension led us to postulate a possible role of MG in the
development of obesity. The development of obesity involves both
adipocyte hypertrophy and hyperplasia [17,18]. While imbalanced
energy intake-induced adipocyte hypertrophy is responsible for
most adult-onset obesity, obesity in childhood may be due to
adipocyte hyperplasia [19,20]. However, proliferation of adipo-
cytes is also observed in adult obesity. Recently, the roles of PI3K/
Akt pathway and its downstream effectors in adipogenesis
especially the proliferation of pre-adipocytes were reported
[21,22,23,24,25,26]. It was found that Akt phosphorylates
cyclin-dependent-kinase (Cdk) inhibitors, p27 and p21, prevents
the localization of these proteins to nucleus, and attenuates their
inhibitory effect on Cdk2. Thus, the cell cycle progression from G1
to S phase is accelerated [27,28,29]. As Akt1 is one of the main
Akt isoforms that related to cell proliferation, it is likely that MG
may act through modifying the Akt1 activity and resulted in cell
proliferation and growth.
An inhibitory effect of MG on cell growth by inducing
apoptosis was studied [30,31,32]. It is reported that MG
promoted programmed cell death through several signaling
pathways including growth factor receptor and the gp130/
STAT3-signaling pathway. However, the concentrations of MG
(100 to 500 mM) causing apoptosis were much greater than the
physiological concentration, which is 1.81–3.29 mM in normal
Sprague-Dawley rats [33] and 3.3–5.9 mM in healthy and
diabetic humans [12]. The effects of MG at physiological or
pathological levels on cell growth need to be further explored.
In the present study, we used 3T3-L1 cells, a widely used
adipocyte-like cell line, to test whether MG contributes to the
development of obesity through stimulating adipocyte pro-
liferation [34].
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Increased Akt1 Phophorylation Associated with MG
Accumulation in Obese Rats
It was reported that plasma level of MG was increased in rats
with diabetes and hypertension [12,35,36,37,38]. To examine the
correlation between MG accumulation and the development of
obesity, we compared the MG accumulation in the white fat
tissues from Zucker lean and obese rats. At the age of 16 weeks,
the body weight of the obese rats was significantly greater than
that of the lean rats (Table 1), which is consistent with an increased
adipose tissue deposit in obese rats (data not shown). Obese rats
also exhibited higher serum triglyceride (TG), higher total
cholesterol (Chol), but significantly decreased high-density choles-
terol (HDL) level comparing with those of lean rats (Table 1).
Although the fasting glucose level did not show significant
difference between lean and obese rats at the ages of 10, 12, 14
and 16 weeks (Table 1), a markedly increased MG accumulation
was observed in kidney, and fat tissue of obese rats at age of 16
weeks (Fig. 1A). In addition, MG level was shown accumulated in
serum of obese rats (13.4661.13 mM vs 4.0860.94 mM in lean
rats). With the increased MG accumulation, a decreased GSH
level was observed in obese rats (Fig. 1B). However, the activity of
glyoxalase I, the major enzyme detoxifying MG, did not show
significant change (Fig. 1C), suggesting that elevated MG level may
be mainly related to MG formation.
As Akt1 is the isoform that contributes to cell proliferation and
cell growth, we studied the phosphorylation levels of Akt1 isoform
in adipose tissues from Zucker lean and obese rats at the age of 16
weeks. Significantly elevated levels of phospho-Akt1(S473) and
phospho-Akt1(T308), two activation sites of Akt1 kinase, were
observed in Zucker obese rats as compared to that of Zucker lean
rats (Fig. 1D,E).
MG Stimulated Proliferation of Cultured 3T3-L1 Cells
To investigate whether MG treatment could induce the
proliferation of 3T3-L1 cells, we carried out a cell proliferation
assay with or without MG treatment (1.25,50 mM). MG at 5,
10 and 20 mM increased the proliferation rate of 3T3-L1 cells
to 11562.1%, 12663.6% and 11963.3% of the untreated cells
(P,0.05 vs. control; n=48 in each group, Fig. 2A). The co-
treatment with Akt inhibitor SH-6 (10 mM) or the AGE
lowering reagent alagebrium (50 mM) prevented the MG-
induced cell proliferation (Fig. 2B). When 3T3-L1 cells were
treated with MG (5,50 mM), the GSH level was significantly
decreased. Consistent with the results from animal study,
gloxalase I activity were not significantly altered by MG
treatment (Fig. 2C, D).
The effect of MG on cell proliferation was further confirmed
by analysis of the cell cycle phase distribution after MG
treatment (Fig. 3). Comparing the cell number distributed in
G1, S and G2 cell phase at different time points, we found that
the MG-treatment lead to a faster cell cycle progression
(Fig. 3A), which represented as an increased cell number in S
phase after 16 or 20 h of MG (10 mM) treatment (Fig. 3A–b)
and increased cell number in G2 phase after exposure of cells to
MG (10 mM) for 20 h (Fig. 3A–c). The co-administration of SH-
6 (10 mM) reversed the effect of MG on cell cycle progression in
S and G2 phases (Fig. 3B–b, c). In contrast, increased G1 phase
distribution indicated a longer interdivision time due to the
inhibited rate of mass synthesis in cells co-treated with MG and
SH-6, which reflects the inhibitive effect of SH-6 on Akt.
Correspondingly, there was an increase of S phase cell number
in cells treated with MG alone (Fig. 3B–b). Although reported to
induce cell apoptosis at higher concentrations, 10 mMo fM G
did not increase sub-diploid/apoptotic cells. The percentage of
apoptotic cells was 2.57%, 2.74%, 2.66% and 2.45% re-
spectively for control group, MG-treated group, MG-SH6 and
MG-ALA group.
Effect of MG on Akt1 and its Downstream Targets in 3T3-
L1 Cells
To further understand the mechanism of MG induced cell
proliferation in 3T3-L1 cells, the phosphorylation of Akt1 isoform
was studied in cultured cells. Consistent with our observations of
Akt1 in Zucker obese and lean animals, the levels of phospho-
Akt1(Ser473) and phospho-Akt1(Thr308) in cultured 3T3-L1 cells
were significantly increased after MG treatment (10 and 30 mM)
for 24 h (Fig. 4). Co-application of alagebrium (50 mM) with MG
attenuated the phosphorylation levels on both Ser473 and Thr308
of Akt1. Alagebrium itself had no significant effect on phospho-
Akt1.
As Akt regulates cell growth by phosphorylating p21 and p27
[26], we further examined the effect of MG on p21 and p27 in
3T3-L1 cells (Fig. 5). Consistent with the increased phosphoryla-
tion of Akt1, phosphorylated p21 (p-p21) and p27 (p-p27) were
also observed in 10 mM MG treated 3T3-L1 cells (Fig. 5A),
indicating a role of MG in stimulating Akt1 signaling. Co-
administration of SH-6 (10 mM) or alagebrium (50 mM) signifi-
cantly prevented the increased phosphorylation of p21 and p27
induced by MG.
In another group of experiments, we also examined the effect of
MG on Cdk2 activity in 3T3-L1 cells. As shown in Fig. 5B, after
the cells were treated with MG (10 mM) for 24 h, the activity of
Cdk2 was increased to ,4-fold of the control level. The increased
Cdk2 activity was prevented by co-administration of either SH-6
or alagebrium. However, no significant change in the protein
levels of Cdk2 in the cells treated with or without MG (10 mM) for
24 h was observed (data not shown).
Table 1. Basic parameters of lean/obese Zucker rats.
Bodyweight (g) Lipid profile (mM) Blood glucose (mM)
Chol TG HDL 10 12 14 16wk
Lean 376.469.3 1.260.0 0.460.1 1.060.05 5.460.1 5.660.8 5.060.2 5.760.2
Obese 600.565.7* 2.360.1* 5.561.2** 0.160.1** 5.660.2 5.560.2 5.860.5 6.360.4
*P,0.05,
**P,0.01 vs lean Zucker rats, n=428 in each group.
Chol: total cholesterol, TG: triglyceride, HDL: high density lipoprotein.
doi:10.1371/journal.pone.0036610.t001
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36610Figure 1. Increased MG accumulation, reduced GSH level and glyoxalase I activity were related to Akt1 expression in obese Zucker
rats. (A) MG levels in kidney, fat, liver of 16-week old Zucker lean or obese rats. *P,0.05, n=428 in each groups. (B) GSH level decreased in the
adipose tissue of Zucker obese rats while glyoxalase I activity (C ) remain unchanged compare with Zucker lean rats. GSH level was presented as % of
that in control group. *P,0.05, n=4 in each groups. (D) The expression of p-Akt1 and Akt1 in adipose tissue of lean and obese Zucker rats. *P,0.05,
**P,0.01, n=4 in both groups. The results of Western blotting were quantified by ChemigenusH Bio imaging system company) and presented as the
percentage of that from control cells (E). % Zucker lean rats, & Zucker obese rats.
doi:10.1371/journal.pone.0036610.g001
Figure 2. The effect of MG on 3T3-L1 cell proliferation, GSH level and glyoxalase I activity. The relative cell proliferation of each group
was presented as the ratio between arbitrary absorbance on 570 nm of each group and that from the control group without treatment. The effect of
different MG concentrations on cell proliferation was shown in (A) and the effect of 10 mM MG with/without SH-6 and alagebrium was shown in (B).
The reduced GSH level (C ) and unchanged glyoxalase I activity (D) was observed in 3T3-L1 cells treated with 5, 10, 20 and 50 mM MG. *P,0.05,
**P,0.01 vs control cells;
+P,0.05 vs MG treated cells; n=12 in each group.
doi:10.1371/journal.pone.0036610.g002
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3T3-L1 Cells
We have observed that incubation of 3T3-L1 cells with MG
(10 mM) caused increased cell proliferation. To investigate
whether this associates with a greater number of differentiated
adipocytes, we treated the 3T3-L1 cells with MG, without or with
SH-6 or alagebrium, for 48 h. On the 5th day of post-
differentiation, triglyceride accumulation was indeed increased to
115.761.6% of the control level (Fig. 6A, B). The increased lipid
content in MG-treated cells was attenuated by SH-6 or
alagebrium co-administration. MG treatment (10–30 uM) of
3T3-L1 cells not only upregulates the transcriptional expression
of adiponectin, leptin, PPARc and C/EBPa, four important
adipogenic markers, but also increases cellular adipogenesis
(Fig. 6C). Furthermore, co-treatment of the cells with ALA
efficiently reversed the MG-induced upregulation of these
adipogenic markers.
Discussion
Increased MG levels and MG-related AGEs have been reported
in different insulin resistance states, which is associated with
various clinical manifestations such as hypertension and diabetes
[8,11,39]. However, the correlation between endogenous MG
accumulation and the development of obesity, the major risk
factor for insulin resistance, has not been shown previously. Our
data in this study revealed the higher concentrations of MG in
adipose tissue of obese Zucker rats. The increased basal level Akt1
phosphorylation observed in obese Zucker rats may represent the
consequence of increased MG level in adipose tissue. However, it
may also be related to the increased plasma insulin in obese rats
which was observed in our previous study [40]. To further identify
the effect of MG on Akt1 phosphorylation, we treated 3T3-L1 cells
with MG. MG treatment induced the increases in the phosphor-
ylation of Akt1, p21 and p27, as well as an enhanced activity of
Cdk2 and accelerated cell cycle progression. This result reinforces
the correlation between MG accumulation and Akt1 phosphor-
ylation observed in animal model. Thus, increased MG may be
one of the factors that contribute to increase Akt phosphorylation
in obese animals.
The deleterious effect of MG on different types of cells has been
extensively studied [30,31,32]. A previous study reported an
increased apoptotic cell number when mouse Schwann cells were
treated with 500–1000 mM MG [31]. In another study, MG
(100 mM, [30] altered the PDGF-induced PDGFRb-phosphoryla-
tion, and reduced the proliferation of mesenchymal cells (smooth
muscle cells and skin fibroblasts). The major difference in our
study is that the 3T3-L1 cells were treated with more physiolog-
ically relevant concentrations (1.25,20 mM) of MG compared
with 0.2,5 mM of MG in normal human/rats based on previous
Figure 3. Effect of MG on cell cycle progression of 3T3-L1 cells. After 12, 16, 20 h of MG (10 mM) treatment, cellular DNA content was
determined by a flow cytometer (A). The effect of MG with/without SH6 (10 mM) or alagebrium (50 mM) on cellular DNA content is shown in (B).
*P,0.05 vs control group;
+P,0.05 vs MG treated group; n=6 in each group. The indicated percentage of the cell number is average of three
experiments. CT: control; ALA: alagebrium.
doi:10.1371/journal.pone.0036610.g003
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studies, we observed a decreased proliferation of 3T3-L1 cells
when the MG concentration was increased to 100 mM (data not
shown). This might indicate a biphasic effect of MG on cell
proliferation. Most probably, the inhibitory effect of MG is due to
the acute effect of high MG concentration, but not the effect of
MG at the physiological relevant level. To our knowledge, this is
the first report about the stimulating effect of MG on pre-
adipocytes proliferation. However, this effect may not be limited to
adipocytes. Increased proliferation was also observed in vascular
smooth muscle cells after MG treatment [42] in our other study. In
response to increased MG level, 3T3-L1 cells showed a decreased
GSH level, but glyoxalase I activity remained unchanged (Fig. 2C,
D). Obese rats showed a similar pattern of change in GSH level
and glyoxalase I activity as observed in MG treated cells. The
unchanged glyoxalase I activity suggests that increased MG
accumulation in obese rats may mainly due to increased MG
production. As the consumption of high-carbohydrate food has
increased worldwide, the prevalence of metabolic syndrome such
as diabetes and obesity has also risen. The usage of table sugar
sucrose (1 glucose +1 fructose) and high fructose corn syrup
(HFCS, 55% fructose and 45% glucose) to sweeten beverages
(such as soft drinks) or as an ingredient in processed foods has
increased significantly in the last several decades. Obese Zucker
rats lack leptin receptor. Leptin exerts a negative control on food
intake. Increased food intake due to the absence of leptin receptor
provides a surplus of substrate for MG production in these obese
Zucker rats. Elevated vascular tissue MG levels were reported in
normal SD rats fed with high fructose (60% in diet) for 16 weeks
and in cultured vascular smooth muscle cells treated with high
fructose (25 mM). Putative mechanisms for this MG overproduc-
tion are increased cellular fructose accumulation due to the
upregulation of Glut5 (a transporter for fructose) and aldolase B (a
key enzyme that catalyzes MG formation from fructose) [43]. In
obese Zucker rats, MG levels are elevated in plasma, adipose
tissues, and kidney, but not in the liver (Fig 1). The mechanisms for
MG overproduction in different tissues or organs might be
different and whether adipose tissue and vascular tissue share the
similar mechanism needs further investigation.
The possible underlying mechanism for MG effects on cell
proliferation may related to dAkt1 signal cascade, which plays an
important role in regulating cell proliferation. Based on our results,
the effect of MG on cell proliferation was due to MG-increased
activity of Akt1 and the related targets. In our study, 10 mMo f
MG in cultured 3T3-L1 cells increased the phosphorylation of
Akt1. Furthermore, MG treatment increased the phosphorylation
of p21 and p27 (Fig. 5A), the major regulators that arrest the cell
cycle progression at the G1/S checkpoint. The increased
phosphorylation of p21 and p27 activates their degradation and
leads to the entry of cells to S phase. This explains the MG-
activated cell proliferation detected in our experiment. Further
observation of the increased Cdk2 activity in MG-treated cells
supported this hypothesis (Fig. 5B). Increased Akt1 activity was
observed in MG-treated 3T3-L1 cells suggesting that change in
Akt1, especially its activity, is critical in adipocyte proliferation.
The MG-treated cells also showed more lipid accumulation as well
as increased expression of adipogenic markers. It may be a direct
result of increased cell numbers after MG was administered during
the proliferation stage (Fig. 6).
In the current study, Akt1 not only shows increased phosphor-
ylation level in MG treated adipocytes, but also in adipose tissues
from obese rats with an increase of MG accumulation (Fig. 1, 4
and 5). Moreover, the increased phosphorylation on Akt1 and its
targets (p21 and p27) was efficiently attenuated by AGE lowering
reagent alagebrium. According to our previous study, modification
of a cysteine residue in Akt1 may be favorable for the activation of
Akt1 by phosphorylation on activation sites Ser (473) and Thr
(308) [42]. Findings in this paper suggest that MG mediated Akt1
modification and activation may also contribute to the increased
adipocyte numbers and enlargement of adipose tissue. Alagebrium
Figure 4. Effect of MG on Akt1 phosphorylation in 3T3-L1 cells. After 24 h treatment with or without MG (10 mM) in the presence or absence
of SH-6 (10 mM)/alagebrium (50 mM), the protein levels of Akt1, (A), Representive Western blot of phospho-Akt1 (p-Akt1(Ser473), p-Akt1(thr308)) and
Akt1; (B), The level of phospho-Akt1(Ser473) in 3T3-L1 cells with/without MG treatment; (C ), The level of phospho-Akt1(thr308) in 3T3-L1 cells with/
without MG treatment. *P,0.05 vs control (CT) cells;
+P,0.05 vs MG treated cells. The results were based on data from three experiments. CT: control;
ALA: alagebrium.
doi:10.1371/journal.pone.0036610.g004
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in attenuating the accumulation of extracellular matrix in humans
and animals with diabetic complications. In this study, alagebrium
inhibited the proliferation-provoking effect of MG. It is unlikely
that alagebrium impeded Akt1 activity directly. Instead, it may
function by reversing the MG-induced modification of selective
amino acid residues of Akt1 protein. Various doses (1–100 mM) of
alagebrium have been tested in our preliminary studies. We found
that 50 mM was the optimized concentration of alagebrium and
therefore this concentration was applied throughout the entire
work. This concentration seems higher than the previous reported
doses (1–10 mM) to prevent extracellular matrix and neointima
formation [44]. The dosage of alagebrium applied in different
studies might also relate to different cell types and experimental
conditions. We observed an inhibited Cdk2 activity after ALA
treatment. The most possible reason might still due to the AGE-
lowering effect of ALA because ALA would scavenge the
endogenous produced MG from the cultured cells. However, the
underlying mechanisms of this inhibitive effect need further
investigation.
Obesity in childhood involves both adipocyte hyperplasia and
hypertrophy while adult-onset obesity was generally considered
due to adipocyte hypertrophy. However, various lines of evidence
indicate that adipocyte hyperplasia is also an important factor in
the development of adult-onset obesity, especially morbidly obese
patients with BMI value .39. Since the food intake of obese
Zucker rats is more than lean rats and food over-consumption can
lead to increased MG formation, it is hard to evaluate the extent of
contribution from MG to the development of obesity in Zucker
rats used in this study. However, the results in this study suggest
that MG-stimulated adipogenesis by the up-regulation of Akt
signaling pathway may be a new explanation to the development
of obesity especially the adult-onset morbid obesity.
Materials and Methods
Animals
Eight 8-week-old male obese Zucker rats and eight age-matched
lean Zucker rats were purchased from Charles River laboratories,
Inc. (Wilmington, MA), housed in temperature-regulated animal
facility and maintained at 22–23uC. These animals were exposed
to a 12 h light/dark cycle with free access to water and food. The
standard lab rat chow, ProlabH RMH 3000, contains 60% starch,
22% crude proteins, 5% crude fat, 5% crude fiber, 6% ash, and
2% added minerals (PMIH Nutrition International, St. Louis,
MO). Rats were treated in accordance with guidelines of the
Canadian Council on Animal Care and the experimental
protocols were approved by the Animal Care Committee of the
University of Saskatchewan. At the end of week 16, after overnight
fasting, rats will be anaesthetized with sodium pentobarbital
Figure 5. Effect of MG on p21, p-p21, p27, p-p27 and CDK2 activity in 3T3-L1 cells. After 24 h treatment with or without MG (10 mM) in the
presence or absence of SH-6 (10 mM)/alagebrium (50 mM), the protein levels of p21, p-21 and p27, p-p27 (A), and the activity of Cdk2 (B) were
determined and compared. *P,0.05 vs control (CT) cells;
+P,0.05 vs MG treated cells. The results were based on data from three experiments.
doi:10.1371/journal.pone.0036610.g005
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liver tissues were collected and frozen under 280uC.
Culture and Differentiation of 3T3-L1 Cells
3T3-L1 pre-adipocytes were grown to confluence in Dulbecco’s
modified Eagle’s medium (DMEM, Invitrogen, ON, Canada)
containing 10% bovine calf serum (Invitrogen, ON, Canada). At
two days postconfluence, cell differentiation was induced by
adding insulin (2.5 mg/ml, Sigma, St Louis, MI, USA), dexameth-
asone (0.25 mM, Sigma-Aldrich, MO, USA), and isobutylethyl-
xanthine (IBMX, 0.5 mM, Sigma-Aldrich, MO, USA) to media
for 3 days according to the protocol described previously [45]. The
cells then were grown in post-differentiation media (DMEM
containing 10% fetal calf serum and 2.5 mg/ml insulin). The post-
differentiation medium containing different concentrations of MG
and/or AGE lowering reagent alagebrium was changed every day
until cells were differentiated. Cells were collected by trypsin
digestion after treatments.
MG Measurement
Quantitation of MG used the o-phenylenediamine (o-PD)-based
assay as described by Chaplen et al [46], with some modifications
[11]. Briefly, the supernatant of tissue homogenate or serum was
incubated with 100 mmol/L o-PD for 3 h at room temperature.
The quinoxaline derivative of MG (2-methylquinoxaline) and the
quinoxaline internal standard (5-methylquinoxaline) were then
measured using a Hitachi D-7000 high-performance liquid
chromatography (HPLC) system (Hitachi Ltd., Mississauga,
Ontario, Canada).
Western Blotting
The supernatants containing crude cellular proteins were
resolved on a 12% SDS-PAGE gel, and transferred onto the
PVDF membrane (PALL Corporation, Ontario, Canada). The
membrane was blocked and incubated with different primary
antibodies overnight. After washed 3 times with the PBS-T for
30 min, the membrane was incubated with the HRP-conjugated
secondary antibody for 1 h at room temperature. The immunor-
eactions were visualized by ECL and exposed to X-ray film
(Kodak Scientific Imaging film, X-omat Blue XB-1). The Western
bands were then quantified using ChemigenusH Bio imaging
system and normalized by b-actin.
Cell Proliferation Assay
The proliferation of 3T3-L1 cells was measured by the Celltiter
96H non-radioactive cell proliferation assay kit (Promega, WI,
USA). Briefly, cells were seeded onto 96-well plates (5000 cells per
well) and cultured in Dulbeco’s Modified Eagle’s Medium
(DMEM, HyClone, Ontario, Canada). When they reached
,50% of confluence in medium, the medium was removed and
the cells were washed with serum-free medium and incubated in
serum-free medium for 48 h. The cells were then treated with/
without MG, SH-6 (10 mM, Calbiochem, California, USA) or
alagebrium (50 mM, gift from Synvista Therapeutics, Inc. NJ,
USA) for 48 h in serum-containing DMEM medium supplemen-
ted. The 40% methylglyoxal solution was from Sigma-Aldrich
(MO, USA). To remove the impurities, this commercial solution
was further purified by fractional vacuum distillation. The final
concentration of MG was determined by HPLC and used in the
present study. After treatment, the cells were incubated with dye
solution (15 mL for each well) in medium at 37uC for 4 h and then
incubated with solubilization solution at room temperature for
1 h. The spectrophotometric absorbance of the samples was
determined by using a plate reader (Thermo Labsystems, Finland)
at 570 nm.
Cell Cycle Assay
Cell cycle analysis was performed by propidium iodide (PI)
staining. Briefly, 3T3-L1 cells were firstly seeded into 10 cm
dishes. When they reached ,50% of confluence, the cells were
incubated in serum-free medium for 48 h and then treated with
MG, SH-6 (10 mM) or alagebrium (100 mM) for 12, 16 or 20 h.
Subsequently, the cells were harvested and re-suspended in PBS at
1610
6/mL and fixed with 70% cool ethanol for 1 h. After the cells
were washed and centrifuged, the pelleted cells were re-suspended
in 1 mL PBS and added with 50 mL of RNase A stock solution
(10 g/mL). Followed a 3 h incubation at 4uC, the cells were then
pelleted and added with 1 mL of PI staining solution (3.8 mmol/L
Figure 6. MG induced adipogenesis in 3T3-L1 adipocytes. After
treated with MG, SH-6 or alagebrium for 48 h, cells were cultured till
confluence and differentiation. The Oil Red O staining in adipocytes was
shown in (A). The lipid content in adipocytes from different groups was
quantified and presented as the percentage of that from control cells
(B). The mRNA expression of adiponectin, PPARc, C/EBPa and leptin in
differentiated cells treated with MG alone or with MG and alagebrium
were determined by real-time PCR (C). *P,0.05; **P,0.01; n=3 in each
groups. The open square in Figure 6C represents cells treated with MG;
the stripped square represents cells treated with MG alagebrium. CT:
control; ALA: alagebrium.
doi:10.1371/journal.pone.0036610.g006
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cytometry on an Beckman Coulter Epics XL flow cytometer
(Beckman Coulter Canada Inc, Ontario, Canada). The number of
cells counted in each run was 1,2610
5 cells.
Measurement of Glutathione (GSH) Level and Glyoxalase
I Activity
The monochlorobimane procedure was used to measure GSH
contents as described previously [47]. The GSH-monochlorobi-
mane adduct was measured using a Thermo Labsystems, Finland
microtitre fluorometric reader with excitation at 380 nm and
emission measured at 470 nm. The activity of glyoxalase I was
evaluated by monitoring the increase in absorbance at 240 nm
due to the formation of S-D-lactoylgutathione in the presence of
homogenates. Protein concentrations were determined by bicinch-
oninic acid procedure using bovine serum albumin as the
reference.
CDK2 Activity Assay
CDK2 activity was determined by measuring ATP consumption
with PKLight Assay Kit (Cambrex Bio Science, ME, US) as
described before [42]. Briefly, after incubation of 200 mgo f
proteins with 2 mg of anti-CDK2 antibody (Santa Cruz) in cell lysis
buffer for 4 h at 4uC, protein A/G plus agarose beads (20 mL)
were added and the mixture was incubated overnight at 4uC with
shaking. Beads were washed 3 times and suspended in 40 mLo f
CDK2 kinase assay buffer containing 20 mM ATP and 0.1 mg/mL
histone H1. Above mixture was reacted at 30uC for 30 min in 96-
well plate before kinase stop solution and ATP detection reagent
were added according to the manufacture’s protocol. Biolumines-
cent signal in each well was detected using a microplate
spectrofluorometer (BMG LABTECH Inc., NC, US). CDK2
activity was expressed as ATP consumption from 3 experiments.
Adipogenesis Assay
3T3-L1 cells were treated with/without MG, SH-6 (10 mMo r
alagebrium (50 mM) for 48 h and then continue cultured in fresh
medium. When the cells reached 80% confluence, differentiation
was induced by adding 2.5 mg/ml insulin, 0.25 mM dexametha-
sone (Sigma-Aldrich, MO, USA), and 0.5 mM isobutylmethyl-
xanthine (Sigma-Aldrich, MO, USA) to media for 2 days
according to the protocol described previously [45,48]. The cells
were then grown in post-differentiation medium (DMEM contain-
ing 10% fetal calf serum and 2.5 mg/ml insulin). On the fifth day
of post-differentiation, cells were fixed with 4% (v/v) formaldehyde
in PBS, and then stained with Oil Red solution for 15 min. The
cells were rinsed five times with water and pictures were
photographed under microscope. Cells were considered as being
lipid-positive when droplets were stained red. The dye retained by
the cells was eluted by incubation with 500 ml of isopropanol and
quantified by measuring absorbance at 500 nm by a plate reader
(Thermo Labsystems, Finland).
Real-time PCR
For total-RNA preparation, treated 3T3-L1 cells were homog-
enized in TRIzolH reagent (Invitrogen, ON, Canada) and RNA
was isolated according to the manufacturer’s instructions. Total
RNA was reverse-transcribed in triplicate using RevertAid
TM H
Minus M-MuLV reverse transcriptase (MBI, Fermentas Burling-
ton, ON, Canada) in the presence of 56RT buffer (MBI,
Fermentas, MD, USA), random primer (Invitrogen, Burlington,
ON, Canada), dNTP mixture (Amersham Pittsburgh, PA, USA) at
42uC for 50 min, followed by 72uC for 10 min. The primers of
Leptin were 59- CGGGGCGCTGGTGTAGGGAGATT -39
(sense) and 59- ACACCGCATGGAGAGTCGCAGGAG -39
(antisense). The primers of adiponectin were 59-ATGGG-
TAGTTGCAGTCAGTTGGTA -39 (sense) and 59-
GCCGCTTATGTGTATCGCTCAG -39 (antisense), The pri-
mers of PPARc were 59- AGGGCTTCCGCAGGTTTTTGA -39
(sense) and 59- CACAGGCCGAGAAGGAGAAGC -39 (anti-
sense). The primers of C/EBPa were 59-
CTTGCGCAGGCGGTCATTGTCACT -39 (sense) and 59-
GGCCGGCCTCTTCCCCTACCAG -39 (antisense), The real-
time PCR was carried out in an iCycler iQ apparatus (Bio-Rad,
CA, USA) associated with the ICYCLER OPTICAL SYSTEM
software (version 3.1) using SYBR Green PCR Master Mix (Bio-
Rad).
Data Analysis
Data are expressed as mean 6 SEM and analyzed using one
way ANOVA in conjunction with t test where applicable.
Significant difference between treatments was defined at a level
of P,0.05.
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